MCID: THY128
MIFTS: 49

Thyroid Tumor

Categories: Endocrine diseases, Rare diseases

Aliases & Classifications for Thyroid Tumor

MalaCards integrated aliases for Thyroid Tumor:

Name: Thyroid Tumor 59

Classifications:

Orphanet: 59  
Rare endocrine diseases


External Ids:

UMLS via Orphanet 73 C0040136
Orphanet 59 ORPHA100087

Summaries for Thyroid Tumor

MalaCards based summary : Thyroid Tumor is related to adenoma and papillary carcinoma. An important gene associated with Thyroid Tumor is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Anti-Infective Agents, Local and Micronutrients have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Thyroid Tumor

Diseases related to Thyroid Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 adenoma 31.3 TP53 RET KRAS BRAF
2 papillary carcinoma 31.2 TPO TG RET LGALS3 BRAF
3 follicular adenoma 31.1 TPO TG RET PTEN LGALS3
4 goiter 31.1 TPO THRB TG LGALS3
5 thyroiditis 30.8 TPO THRB TG RET
6 nodular goiter 30.7 TPO TG RET LGALS3
7 hypothyroidism 30.6 TPO THRB TG RET
8 multinodular goiter 30.5 TPO TG HRAS
9 thyroid gland disease 30.4 TPO THRB TG RET LGALS3
10 hashimoto thyroiditis 30.3 TPO TG RET LGALS3 BRAF
11 graves disease 1 30.2 TPO THRB TG
12 hyperthyroidism 30.2 TPO THRB TG
13 thyroid carcinoma, familial medullary 30.0 TG RET KRAS
14 plummer's disease 29.9 TPO THRB TG
15 lipomatosis 29.8 PTEN PRKAR1A PIK3CA
16 testicular germ cell tumor 29.5 TP53 PTEN HRAS BRAF
17 fetal adenoma 28.9 TG NRAS LGALS3 HRAS
18 melanocytic nevus syndrome, congenital 28.9 PRKAR1A NRAS HRAS
19 adenoid cystic carcinoma 28.7 TP53 PTEN PIK3CA KRAS HRAS
20 schimmelpenning-feuerstein-mims syndrome 28.4 NRAS KRAS HRAS
21 sarcoma 28.4 TP53 PIK3CA KRAS HRAS BRAF
22 adenocarcinoma 27.9 TP53 RET PTEN PIK3CA KRAS HRAS
23 differentiated thyroid carcinoma 27.7 TPO TP53 TG RET NRAS KRAS
24 nevus, epidermal 27.7 PIK3CA NRAS KRAS HRAS
25 squamous cell carcinoma 27.6 TP53 PTEN PIK3CA MMP2 HRAS FGFR2
26 thyroid cancer, nonmedullary, 2 27.2 TPO THRB TG RET PTEN PIK3CA
27 melanoma, cutaneous malignant 1 27.1 TP53 TERT PTEN PIK3CA NRAS HRAS
28 prostate cancer 26.6 TP53 TERT PTEN PIK3CA MMP2 KRAS
29 breast cancer 25.8 TP53 TNF TIMP3 TERT PTEN PIK3CA
30 colorectal cancer 24.7 TP53 TNF TERT RET PTEN PIK3CA
31 thyroid carcinoma, nonmedullary, with or without cell oxyphilia 11.7
32 thyroid gland medullary carcinoma 11.5
33 multiple endocrine neoplasia, type iia 11.4
34 thyroid carcinoma 10.9
35 struma ovarii 10.6 TG RET BRAF
36 nevus of ota 10.6 TP53 BRAF
37 subacute lymphocytic thyroiditis 10.6 TPO TG
38 thyroid cancer, nonmedullary, 1 10.6
39 familial thyroid dyshormonogenesis 10.5 TPO TG
40 thyroid gland papillary carcinoma 10.5
41 colloid adenoma 10.5 TP53 TG LGALS3
42 thyroid gland cancer 10.4
43 giant cell glioblastoma 10.4 TP53 PTEN BRAF
44 spermatocele 10.4 TNF TG TERT
45 thyroid hurthle cell adenoma 10.4 PTEN PIK3CA
46 hypothyroidism, thyroidal or athyroidal, with spiky hair and cleft palate 10.4 TPO TG FGFR2
47 bladder squamous cell carcinoma 10.4 TP53 BRAF
48 hypertelorism 10.3 RET FGFR2 BRAF
49 soft tissue sarcoma 10.3 TP53 TNF TERT
50 thyroid gland follicular carcinoma 10.3

Graphical network of the top 20 diseases related to Thyroid Tumor:



Diseases related to Thyroid Tumor

Symptoms & Phenotypes for Thyroid Tumor

GenomeRNAi Phenotypes related to Thyroid Tumor according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.67 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00106-A-0 10.67 KRAS
3 Decreased viability GR00221-A-1 10.67 HRAS KRAS PIK3CA PRKAR1A RET NRAS
4 Decreased viability GR00221-A-2 10.67 HRAS KRAS PIK3CA PRKAR1A RET
5 Decreased viability GR00221-A-3 10.67 HRAS PRKAR1A NRAS
6 Decreased viability GR00221-A-4 10.67 PIK3CA PRKAR1A RET BRAF
7 Decreased viability GR00231-A 10.67 RET
8 Decreased viability GR00301-A 10.67 KRAS RET BRAF FGFR2
9 Decreased viability GR00342-S-1 10.67 FGFR2
10 Decreased viability GR00342-S-2 10.67 FGFR2
11 Decreased viability GR00342-S-3 10.67 FGFR2
12 Decreased viability GR00381-A-1 10.67 KRAS BRAF
13 Decreased viability GR00402-S-2 10.67 HRAS KRAS PIK3CA PRKAR1A RET BRAF
14 Decreased cell migration GR00055-A-1 9.55 BRAF HRAS KRAS PIK3CA PRKAR1A
15 Increased cell migration GR00055-A-3 8.92 BRAF HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Thyroid Tumor:

46 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.57 BRAF FGFR2 HRAS KRAS LGALS3 MMP2
2 homeostasis/metabolism MP:0005376 10.52 BRAF FGFR2 HRAS KRAS LGALS3 MMP2
3 hematopoietic system MP:0005397 10.51 BRAF FGFR2 KRAS LGALS3 MMP2 NRAS
4 immune system MP:0005387 10.51 BRAF FGFR2 KRAS LGALS3 MMP2 NRAS
5 cardiovascular system MP:0005385 10.5 BRAF FGFR2 HRAS KRAS LGALS3 MMP2
6 cellular MP:0005384 10.5 BRAF FGFR2 KRAS LGALS3 NRAS PIK3CA
7 endocrine/exocrine gland MP:0005379 10.5 BRAF FGFR2 HRAS KRAS NRAS PIK3CA
8 digestive/alimentary MP:0005381 10.49 BRAF FGFR2 HRAS KRAS LGALS3 NRAS
9 behavior/neurological MP:0005386 10.48 BRAF FGFR2 HRAS KRAS LGALS3 NRAS
10 mortality/aging MP:0010768 10.46 BRAF FGFR2 HRAS KRAS LGALS3 MMP2
11 craniofacial MP:0005382 10.36 BRAF FGFR2 HRAS KRAS MMP2 NRAS
12 neoplasm MP:0002006 10.35 BRAF FGFR2 HRAS KRAS LGALS3 MMP2
13 integument MP:0010771 10.33 BRAF FGFR2 HRAS KRAS LGALS3 NRAS
14 embryo MP:0005380 10.3 BRAF FGFR2 KRAS NRAS PIK3CA PRKAR1A
15 nervous system MP:0003631 10.3 BRAF FGFR2 HRAS KRAS LGALS3 MMP2
16 adipose tissue MP:0005375 10.29 BRAF FGFR2 LGALS3 PIK3CA PRKAR1A PTEN
17 limbs/digits/tail MP:0005371 10.28 BRAF FGFR2 KRAS NRAS PTEN RET
18 muscle MP:0005369 10.27 BRAF FGFR2 KRAS MMP2 PIK3CA PRKAR1A
19 liver/biliary system MP:0005370 10.22 BRAF FGFR2 KRAS LGALS3 NRAS PRKAR1A
20 normal MP:0002873 10.14 BRAF FGFR2 HRAS KRAS MMP2 NRAS
21 no phenotypic analysis MP:0003012 10.09 FGFR2 HRAS KRAS NRAS PIK3CA RET
22 hearing/vestibular/ear MP:0005377 10.06 BRAF FGFR2 KRAS THRB TP53 TPO
23 reproductive system MP:0005389 10.03 BRAF FGFR2 KRAS LGALS3 PIK3CA PRKAR1A
24 respiratory system MP:0005388 10.03 BRAF FGFR2 HRAS KRAS LGALS3 MMP2
25 pigmentation MP:0001186 9.97 BRAF FGFR2 KRAS NRAS PRKAR1A PTEN
26 renal/urinary system MP:0005367 9.97 BRAF FGFR2 HRAS KRAS LGALS3 PTEN
27 skeleton MP:0005390 9.89 BRAF FGFR2 HRAS KRAS LGALS3 MMP2
28 vision/eye MP:0005391 9.44 BRAF FGFR2 KRAS MMP2 NRAS PIK3CA

Drugs & Therapeutics for Thyroid Tumor

Drugs for Thyroid Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anti-Infective Agents, Local Phase 4
2 Micronutrients Phase 4
3 Nutrients Phase 4
4 Trace Elements Phase 4
5 Anti-Infective Agents Phase 4
6 Hemostatics Phase 3
7 Coagulants Phase 3
8
Iodine Approved, Investigational 7553-56-2 807
9
Dexmedetomidine Approved, Vet_approved 113775-47-6 68602 5311068
10
Desflurane Approved 57041-67-5 42113
11
Remifentanil Approved 132875-61-7 60815
12 cadexomer iodine
13 Neurotransmitter Agents
14 Adrenergic Agonists
15 Analgesics, Non-Narcotic
16 Adrenergic alpha-2 Receptor Agonists
17 Narcotics
18 Analgesics
19 Peripheral Nervous System Agents
20 Adrenergic alpha-Agonists
21 Central Nervous System Depressants
22 Hypnotics and Sedatives
23 Anesthetics
24 Adrenergic Agents
25 Analgesics, Opioid
26 Anesthetics, General
27 Anesthetics, Inhalation

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
2 Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy Unknown status NCT01551914 Phase 3
3 Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study Unknown status NCT00103155 Phase 1
4 Clinical Benefits of Reduced Subcutaneous Dissection in Endoscopic Thyroidectomy Unknown status NCT01338597
5 Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry Unknown status NCT01668238
6 Purse String Suture for the Closure of Large Thyroidectomy Resulted in Better Cosmetics Completed NCT03035383
7 Significant Intracellular NIS Protein Associated With Low Levels of NIS Messenger RNA in Malignant Thyroid Tumors Completed NCT00459498
8 Levothyroxine Treatment in Thyroid Benign Nodular Goiter Completed NCT00552253 Levothyroxin treatment
9 Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study Completed NCT01265381
10 Prospective and Retrospective Thyroid Cancer Database Recruiting NCT04031638
11 Clinical and Genetic Studies in Familial Non-Medullary Thyroid Cancer Recruiting NCT01109420
12 Significance of Single Center, Open and Prospective Evaluation of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma. Recruiting NCT03845647
13 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
14 Effect of Dexmedetomidine Infusion for Postoperative Outcome and Smooth Emergence After Thyroidectomy Recruiting NCT02412150 Desflurane;Remifentanil;Dexmedetomidine;Normal saline
15 Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging in Detecting Metastatic Central Lymph Nodes in Patients With Papillary Thyroid Cancer Recruiting NCT03830242
16 Longitudinal Assessment and Natural History Study of Children and Adults With MEN2A or MEN2B With or Without Medullary Thyroid Carcinoma Recruiting NCT01660984

Search NIH Clinical Center for Thyroid Tumor

Genetic Tests for Thyroid Tumor

Anatomical Context for Thyroid Tumor

MalaCards organs/tissues related to Thyroid Tumor:

41
Thyroid, Lymph Node, Breast, Lung, Endothelial, Bone, Thymus

Publications for Thyroid Tumor

Articles related to Thyroid Tumor:

(show top 50) (show all 1377)
# Title Authors PMID Year
1
Thyroid autoimmune diseases and thyroid tumors: Would EBV infection be the link? 38
31120135 2019
2
TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up. 38
31154561 2019
3
Prognostic Impact of the Turin Criteria in Poorly Differentiated Thyroid Carcinoma. 38
31098668 2019
4
MOLECULAR PROFILE AND CLINICAL OUTCOMES IN DIFFERENTIATED THYROID CANCER PATIENTS PRESENTING WITH BONE METASTASIS. 38
31412230 2019
5
Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. 38
31097454 2019
6
Significance and management of incidentally diagnosed metastatic papillary thyroid carcinoma in cervical lymph nodes in neck dissection specimens. 38
31390117 2019
7
Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma. 38
31298630 2019
8
A Comparative Study of ARHI Imprinted Gene Detection and Fine-Needle Aspiration Cytology in the Differential Diagnosis of Benign and Malignant Thyroid Nodules. 38
31411490 2019
9
Synergistic repression of thyroid hyperplasia by cyclin C and Pten. 38
31331961 2019
10
Osteoclastic variant of anaplastic thyroid carcinoma: A case report of rare entity. 38
31169246 2019
11
Thyroid-like follicular carcinoma of the kidney presenting on a 10 year-old prepubertal girl. 38
31063281 2019
12
Long noncoding RNA RP11-547D24.1 regulates proliferation and migration in papillary thyroid carcinoma: Identification and validation of a novel long noncoding RNA through integrated analysis of TCGA database. 38
31044550 2019
13
Clinicopathological Significance of Overall Frequency of Allelic Loss (OFAL) in Lesions Derived from Thyroid Follicular Cell. 38
30747408 2019
14
Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1. 38
31189769 2019
15
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma. 38
31053251 2019
16
Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer. 38
30361380 2019
17
Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. 38
31189135 2019
18
Dysbiosis of the gut microbiome is associated with thyroid cancer and thyroid nodules and correlated with clinical index of thyroid function. 38
30584647 2019
19
Analysis of thyroid thermographic images for detection of thyroid tumor: An experimental-numerical study. 38
30801998 2019
20
Typical manifestations of Hürthle cell adenoma of the thyroid on contrast-enhanced CT: A case report. 38
31145341 2019
21
Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism. 38
31113465 2019
22
Role of chemokine receptors in thyroid cancer and immunotherapy. 38
31146261 2019
23
Clear Cell Variant of a Follicular Thyroid Tumor With Uncertain Malignant Potential: A Case Report. 38
30370813 2019
24
Thyroid peroxidase as a dual active site enzyme: Focus on biosynthesis, hormonogenesis and thyroid disorders of autoimmunity and cancer. 38
30742860 2019
25
Mutation profiles of follicular thyroid tumors by targeted sequencing. 38
31077238 2019
26
Important cytological findings for distinction between follicular variant and conventional papillary thyroid carcinoma, including noninvasive follicular thyroid tumors with papillary-like nuclear features. 38
30867345 2019
27
Cribriform-Morular Variant of Papillary Thyroid Carcinoma With Poorly Differentiated Features: A Case Report With Immunohistochemical and Molecular Genetic Analysis. 38
30176755 2019
28
LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES. 38
30657361 2019
29
PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway. 38
30851633 2019
30
Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. 38
30762153 2019
31
Impact of the new guidelines of the American Thyroid Association on the treatment of the differentiated thyroid tumor in an Italian center with medium-high volume thyroid surgery. 38
31074397 2019
32
Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells. 38
31027376 2019
33
Epstein-Barr virus and thyroid cancer: The role of viral expressed proteins. 38
30362517 2019
34
Estimation of thyroid volume from scintigraphy through 2D/3D registration of a statistical shape model. 38
30974417 2019
35
miR-544 inhibits the migration and invasion of anaplastic thyroid cancer by targeting Yin Yang-1. 38
30854076 2019
36
Chondroma of laryngeal cartilage mimicking thyroid tumor: A case report. 38
30921219 2019
37
Encapsulated Papillary Thyroid Tumor with Delicate Nuclear Changes and a KRAS Mutation as a Possible Novel Subtype of Borderline Tumor. 38
30636389 2019
38
Clear cell renal carcinoma metastasis mimicking primary thyroid tumor. 38
30688287 2019
39
Impact of tumor-associated macrophages and BRAFV600E mutation on clinical outcomes in patients with various thyroid cancers. 38
30659691 2019
40
GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. 38
30648929 2019
41
Adamantinoma-Like Ewing Sarcoma of the Thyroid: A Case Report and Review of the Literature. 38
30734898 2019
42
CircRNA circ_0067934 Overexpression Correlates with Poor Prognosis and Promotes Thyroid Carcinoma Progression. 38
30779728 2019
43
Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells. 38
30445205 2019
44
Diagnostic value of ultrasonography and TI-201/Tc-99m dual scintigraphy in differentiating between benign and malignant thyroid nodules. 38
30276595 2019
45
Surgical treatment result of giant thyroid tumor: Case series in Vietnam. 38
30599302 2019
46
Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. 38
31285773 2019
47
Expression of ANGPTL2 and its impact on papillary thyroid cancer. 38
31384179 2019
48
Podoplanin (PDPN) affects the invasiveness of thyroid carcinoma cells by inducing ezrin, radixin and moesin (E/R/M) phosphorylation in association with matrix metalloproteinases. 38
30654768 2019
49
A prospective follow-up study on completion thyroidectomy for well-differentiated thyroid cancer. A single-center report. 38
30862767 2019
50
[Clinical and morphological characteristics of thyroid tumors in children of the Chelyabinsk Region]. 38
31407719 2019

Variations for Thyroid Tumor

ClinVar genetic disease variations for Thyroid Tumor:

6 (show all 41)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 KRAS NM_004985.5(KRAS): c.37G> A (p.Gly13Ser) single nucleotide variant Pathogenic rs121913535 12:25398282-25398282 12:25245348-25245348
2 KRAS NM_004985.5(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
3 KRAS NM_004985.5(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 12:25398281-25398281 12:25245347-25245347
4 KRAS NM_004985.5(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 12:25398282-25398282 12:25245348-25245348
5 KRAS NM_004985.5(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 12:25398284-25398284 12:25245350-25245350
6 KRAS NM_004985.5(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 12:25398284-25398284 12:25245350-25245350
7 KRAS NM_004985.5(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
8 HRAS NM_005343.4(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
9 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
10 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
11 RET NM_020630.5(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic rs77709286 10:43609950-43609950 10:43114502-43114502
12 RET NM_020630.5(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 10:43617416-43617416 10:43121968-43121968
13 BRAF NM_004333.6(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 7:140453134-140453134 7:140753334-140753334
14 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
15 KRAS NM_004985.5(KRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic rs1057519725 12:25378561-25378561 12:25225627-25225627
16 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
17 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
18 KRAS NM_004985.5(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic rs121913240 12:25380276-25380276 12:25227342-25227342
19 KRAS NM_004985.5(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 12:25380276-25380276 12:25227342-25227342
20 KRAS NM_004985.5(KRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic rs121913238 12:25380277-25380277 12:25227343-25227343
21 NRAS NM_002524.5(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
22 HRAS NM_005343.4(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 11:534286-534286 11:534286-534286
23 KRAS NM_004985.5(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
24 PIK3CA NM_006218.4(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 3:178952074-178952074 3:179234286-179234286
25 KRAS NM_004985.5(KRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913240 12:25380276-25380276 12:25227342-25227342
26 NRAS NM_002524.5(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
27 HRAS ; LRRC56 NM_005343.4(HRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 11:534289-534289 11:534289-534289
28 BRAF NM_004333.6(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 7:140453133-140453133 7:140753333-140753333
29 KRAS NM_004985.5(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 12:25380275-25380275 12:25227341-25227341
30 PIK3CA NM_006218.4(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 3:178917478-178917478 3:179199690-179199690
31 HRAS NM_005343.4(HRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Likely pathogenic rs121913233 11:533874-533874 11:533874-533874
32 KRAS NM_004985.5(KRAS): c.38G> T (p.Gly13Val) single nucleotide variant drug response rs112445441 12:25398281-25398281 12:25245347-25245347
33 HRAS ; LRRC56 NM_005343.4(HRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Likely pathogenic rs121913233 11:533874-533874 11:533874-533874
34 BRAF NM_004333.6(BRAF): c.1803A> C (p.Lys601Asn) single nucleotide variant Likely pathogenic rs121913365 7:140453132-140453132 7:140753332-140753332
35 HRAS NM_005343.4(HRAS): c.183G> T (p.Gln61His) single nucleotide variant Likely pathogenic rs121913496 11:533873-533873 11:533873-533873
36 HRAS ; LRRC56 NM_005343.4(HRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Likely pathogenic rs121913233 11:533874-533874 11:533874-533874
37 HRAS ; LRRC56 NM_005343.4(HRAS): c.181C> G (p.Gln61Glu) single nucleotide variant Likely pathogenic rs28933406 11:533875-533875 11:533875-533875
38 PIK3CA NM_006218.4(PIK3CA): c.3127A> G (p.Met1043Val) single nucleotide variant Likely pathogenic rs1057519936 3:178952072-178952072 3:179234284-179234284
39 PIK3CA NM_006218.4(PIK3CA): c.3128T> C (p.Met1043Thr) single nucleotide variant Likely pathogenic rs1057519937 3:178952073-178952073 3:179234285-179234285
40 PIK3CA NM_006218.4(PIK3CA): c.3127A> T (p.Met1043Leu) single nucleotide variant Likely pathogenic rs1057519936 3:178952072-178952072 3:179234284-179234284
41 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Uncertain significance rs121434592 14:105246551-105246551 14:104780214-104780214

Expression for Thyroid Tumor

Search GEO for disease gene expression data for Thyroid Tumor.

Pathways for Thyroid Tumor

Pathways related to Thyroid Tumor according to GeneCards Suite gene sharing:

(show top 50) (show all 153)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.3 TP53 TNS3 TNF TERT RET PTEN
2
Show member pathways
14.15 TP53 TNF RET PTEN PRKAR1A PIK3CA
3
Show member pathways
13.99 TP53 TNF TIMP3 TERT PTEN PRKAR1A
4
Show member pathways
13.97 TP53 TNF TIMP3 PTEN PRKAR1A NRAS
5
Show member pathways
13.83 TP53 TIMP3 PRKAR1A NRAS MMP2 KRAS
6
Show member pathways
13.67 TP53 TNF TIMP3 PIK3CA NRAS KRAS
7
Show member pathways
13.63 TNF RET PIK3CA NRAS MMP2 KRAS
8
Show member pathways
13.54 TP53 TNF TIMP3 PTEN NRAS KRAS
9
Show member pathways
13.53 PTEN PRKAR1A PIK3CA NRAS MMP2 KRAS
10
Show member pathways
13.47 TP53 TNF RET PIK3CA NRAS MMP2
11
Show member pathways
13.44 TIMP3 PTEN PRKAR1A NRAS KRAS HRAS
12
Show member pathways
13.43 TP53 TIMP3 PRKAR1A PIK3CA NRAS KRAS
13
Show member pathways
13.43 TNF TIMP3 PTEN PRKAR1A NRAS KRAS
14
Show member pathways
13.41 TNF TIMP3 PRKAR1A NRAS KRAS HRAS
15
Show member pathways
13.34 TP53 TNF PTEN PRKAR1A NRAS KRAS
16
Show member pathways
13.19 TP53 TIMP3 PTEN NRAS KRAS HRAS
17
Show member pathways
13.16 TIMP3 PRKAR1A NRAS KRAS HRAS FGFR2
18
Show member pathways
13.1 TP53 TNF PTEN PIK3CA NRAS KRAS
19
Show member pathways
13.09 TP53 TNF PTEN PIK3CA NRAS KRAS
20
Show member pathways
13.09 TP53 TNF TERT PTEN PIK3CA NRAS
21
Show member pathways
13.06 TNF PTEN PRKAR1A NRAS KRAS HRAS
22
Show member pathways
13.05 TP53 TNF PRKAR1A PIK3CA NRAS KRAS
23
Show member pathways
13.04 PTEN PRKAR1A PIK3CA NRAS KRAS HRAS
24
Show member pathways
13.03 PTEN PIK3CA NRAS KRAS HRAS BRAF
25
Show member pathways
13.02 PRKAR1A PIK3CA NRAS KRAS HRAS BRAF
26
Show member pathways
13 PTEN PRKAR1A PIK3CA NRAS KRAS HRAS
27
Show member pathways
12.95 PIK3CA NRAS KRAS HRAS FGFR2
28
Show member pathways
12.95 TP53 TNF PIK3CA NRAS KRAS HRAS
29
Show member pathways
12.92 PIK3CA NRAS KRAS HRAS BRAF
30
Show member pathways
12.92 TNF PTEN PIK3CA KRAS HRAS BRAF
31
Show member pathways
12.92 TP53 RET PTEN PIK3CA NRAS KRAS
32
Show member pathways
12.91 PRKAR1A NRAS KRAS HRAS BRAF
33 12.9 TP53 TNF NRAS KRAS HRAS FGFR2
34
Show member pathways
12.87 PIK3CA NRAS KRAS HRAS FGFR2 BRAF
35
Show member pathways
12.86 TP53 PTEN PIK3CA NRAS KRAS HRAS
36
Show member pathways
12.85 TP53 PTEN PIK3CA NRAS KRAS HRAS
37
Show member pathways
12.82 TP53 TNF NRAS KRAS HRAS BRAF
38
Show member pathways
12.81 PTEN PIK3CA NRAS MMP2 KRAS HRAS
39
Show member pathways
12.79 PRKAR1A NRAS KRAS HRAS BRAF
40 12.78 PIK3CA NRAS KRAS HRAS FGFR2 BRAF
41
Show member pathways
12.75 TP53 TERT PTEN PIK3CA NRAS KRAS
42
Show member pathways
12.73 TNF PTEN PIK3CA NRAS KRAS HRAS
43
Show member pathways
12.73 TP53 PIK3CA NRAS KRAS HRAS BRAF
44
Show member pathways
12.73 TP53 TNF PIK3CA NRAS MMP2 KRAS
45
Show member pathways
12.72 PIK3CA NRAS KRAS HRAS FGFR2 BRAF
46
Show member pathways
12.71 TNF PIK3CA NRAS KRAS HRAS
47
Show member pathways
12.71 TP53 PTEN PIK3CA NRAS MMP2 KRAS
48
Show member pathways
12.66 TNF PIK3CA NRAS KRAS HRAS BRAF
49 12.66 TP53 TIMP3 PTEN PIK3CA NRAS KRAS
50
Show member pathways
12.63 PTEN PIK3CA NRAS KRAS HRAS

GO Terms for Thyroid Tumor

Cellular components related to Thyroid Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.47 TPO TNF TERT RET PTEN PRKAR1A
2 PML body GO:0016605 9.13 TP53 TERT PTEN

Biological processes related to Thyroid Tumor according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.9 PTEN PIK3CA MMP2 FGFR2
2 positive regulation of protein kinase B signaling GO:0051897 9.85 TNF RET PIK3CA FGFR2
3 cytokine-mediated signaling pathway GO:0019221 9.83 TP53 TNF PIK3CA MMP2 KRAS
4 response to organic substance GO:0010033 9.8 TNF TIMP3 PTEN
5 negative regulation of apoptotic process GO:0043066 9.8 TP53 TERT PTEN BRAF
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.78 TNF PIK3CA BRAF
7 regulation of protein stability GO:0031647 9.77 TERT PTEN KRAS
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.76 NRAS KRAS HRAS
9 positive regulation of MAP kinase activity GO:0043406 9.75 TNF KRAS HRAS
10 negative regulation of neuron apoptotic process GO:0043524 9.72 TERT PIK3CA KRAS HRAS BRAF
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.7 TNF TERT MMP2
12 protein kinase B signaling GO:0043491 9.69 TNF PTEN PIK3CA
13 Ras protein signal transduction GO:0007265 9.67 TP53 NRAS KRAS HRAS
14 animal organ morphogenesis GO:0009887 9.65 TNF THRB HRAS FGFR2 BRAF
15 regulation of synaptic transmission, GABAergic GO:0032228 9.63 PTEN KRAS
16 replicative senescence GO:0090399 9.62 TP53 TERT
17 hormone biosynthetic process GO:0042446 9.61 TPO TG
18 thyroid gland development GO:0030878 9.58 THRB TG BRAF
19 response to isolation stress GO:0035900 9.57 KRAS HRAS
20 regulation of axon regeneration GO:0048679 9.56 PTEN BRAF
21 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 TNF PTEN HRAS FGFR2 BRAF
22 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.54 TNF FGFR2
23 positive regulation of gene expression GO:0010628 9.5 TP53 TNF RET PTEN KRAS HRAS
24 positive regulation of TRAIL-activated apoptotic signaling pathway GO:1903984 9.48 TIMP3 PTEN
25 positive regulation of mononuclear cell migration GO:0071677 9.46 TNF LGALS3
26 MAPK cascade GO:0000165 9.17 TNF RET NRAS KRAS HRAS FGFR2
27 cell differentiation GO:0030154 10.04 TP53 THRB RET LGALS3 BRAF
28 positive regulation of cell proliferation GO:0008284 10.02 TNS3 PTEN KRAS HRAS FGFR2

Molecular functions related to Thyroid Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 TP53 TNS3 TNF TIMP3 THRB TERT
2 nucleotide binding GO:0000166 9.1 RET NRAS KRAS HRAS FGFR2 BRAF

Sources for Thyroid Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....